PNC Financial Services Group Inc. Has $18.47 Million Stock Position in Humana Inc. (NYSE:HUM)

PNC Financial Services Group Inc. reduced its holdings in Humana Inc. (NYSE:HUM - Free Report) by 10.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 72,809 shares of the insurance provider's stock after selling 8,385 shares during the period. PNC Financial Services Group Inc. owned about 0.06% of Humana worth $18,472,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Humana in the 4th quarter worth about $86,000. AMG National Trust Bank acquired a new position in Humana in the 4th quarter worth about $1,510,000. Edgestream Partners L.P. increased its position in Humana by 372.1% in the 4th quarter. Edgestream Partners L.P. now owns 13,515 shares of the insurance provider's stock worth $3,429,000 after purchasing an additional 10,652 shares during the last quarter. Prescott Group Capital Management L.L.C. increased its position in Humana by 100.0% in the 4th quarter. Prescott Group Capital Management L.L.C. now owns 11,464 shares of the insurance provider's stock worth $2,909,000 after purchasing an additional 5,732 shares during the last quarter. Finally, BBR Partners LLC acquired a new position in Humana in the 4th quarter worth about $5,393,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of HUM stock traded down $1.04 during mid-day trading on Tuesday, reaching $250.21. The stock had a trading volume of 1,387,813 shares, compared to its average volume of 1,676,635. The firm's 50 day simple moving average is $271.74 and its 200 day simple moving average is $282.37. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The firm has a market cap of $30.19 billion, a PE ratio of 25.15, a P/E/G ratio of 2.05 and a beta of 0.57.

Remove Ads

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.41%. Humana's dividend payout ratio (DPR) is presently 35.58%.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of the firm's stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.32% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HUM. Morgan Stanley dropped their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. JPMorgan Chase & Co. dropped their target price on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 18th. Truist Financial upped their target price on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a research report on Monday, January 6th. Barclays upped their target price on Humana from $255.00 to $270.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 13th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Twenty research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Humana has an average rating of "Hold" and an average target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.